The evidence behind every product.

Our actives are inside finished products, and every study behind them is a click away.

Already inside products people buy.

Each one below has been tested in people, shown with its study design and images.

Kristen Claire Premium Scalp Essence ampoules
Clinical Trial · Randomized · Placebo-controlled

Kristen Claire Premium Scalp Essence

The essence in this trial uses our ExoBella® Centella exosomes with AvaFactor™ IGF-1 and FGF-7. In a randomized, placebo-controlled trial published in Cosmetics, it cut hair loss by 63.6% by day 56.

60
Participants
56
Days
IRB
Approved · NCT06985121

Day 0 and Day 56

Standardized photography from the randomized, placebo-controlled scalp-essence trial.

Scalp at day zero, trial baseline
Day 0Baseline
Scalp at day fifty-six, end of trial
Day 56End of trial
Lash serum built on Halyra regenerative actives
Clinical Pilot · Randomized · Double-blind · Placebo-controlled

A lash serum, tested double-blind.

A lash serum made with our long-acting AvaFactor™ IGF-1 and FGF-7, with ExoZina™ ginger and ExoCurma™ turmeric exosomes, applied twice daily for eight weeks. Lash density and length were measured with a standardized imaging system and compared against placebo. Posted as a preprint on medRxiv, September 2026.

30
Participants
8
Weeks
1:1
Active to placebo

Baseline and follow-up

Standardized imaging from the randomized, double-blind eyelash study.

Upper eyelashes of one participant at baseline and at follow-up, with magnified views of the center and the outer third
Finished retail facial serum built on ExoBella Cica exosomes
Clinical Pilot · Placebo-compared

A finished facial serum, in market.

A retail facial serum built on our ExoBella® Centella exosomes, assessed over 28 days. Hydration, elasticity, melanin, wrinkles, redness and pore size were each quantified with instrumental probes and a standardized imaging system.

20
Treated participants
10
Placebo comparison
28
Days · NCT06850935

Day 0 and Day 28

Standardized facial imaging from the instrumented skin-quality pilot.

Facial skin at day zero, pilot baseline
Day 0Baseline
Facial skin at day twenty-eight, end of pilot
Day 28End of pilot

How the platform is built.

Three technologies sit behind every active we make.

Plant Stem CellsPlant callus, grown under optimized conditions, with proprietary exosome separation
Recombinant expressionBioreactor-expressed growth factors carrying a protective, stabilizing fusion domain
NTA and TEMParticle count, size distribution and morphology confirmed batch to batch

The papers behind the platform.

Randomized · Placebo-controlled

Cica extracellular vesicle and growth-factor essence for hair and scalp ↗

Cosmetics 2025, 12, 253 · DOI 10.3390/cosmetics12060253 · 56-day trial · n=60 · IRB-approved · NCT06985121

A randomized, placebo-controlled clinical trial of a Cica exosome scalp essence combining long-acting recombinant IGF-1 and FGF-7. Hair loss fell by 63.6% by day 56, against 43.1% with placebo. This is the strongest human evidence on the platform.

Read the paper ↗
Preprint · Randomized

Dual-species extracellular vesicle and growth-factor formulation for hair and scalp ↗

medRxiv preprint, posted 10 September 2026 · in peer review · DOI 10.64898/2026.09.07.26362401 · 56 days · n=60 · five study arms

A randomized, placebo-controlled study of Centella asiatica and ginger exosomes with long-acting recombinant IGF-1 and FGF-7. Scalp and hair were measured at days 14, 28, 42 and 56. With the full combination, hair shedding fell by almost half by day 56, ahead of each technology on its own.

Read the preprint ↗
Preprint · Double-blind

Multi-herbal extracellular vesicle and growth-factor serum for eyelash care ↗

medRxiv preprint, posted 10 September 2026 · DOI 10.64898/2026.09.06.26360639 · 8 weeks · n=30

A randomized, double-blind, placebo-controlled pilot of a lash serum combining long-acting recombinant IGF-1 and FGF-7 with ginger and turmeric exosomes. Lash density and length were measured by standardized imaging at weeks 4 and 8. Periocular pigmentation stayed unchanged.

Read the preprint ↗

Want these actives in your products?

A person from our team replies within a few days.